DOCSLIB.ORG

Media Kit2o2o

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Media Kit2o2o MEDIA KIT 2O2O prix galien usa NEW YORK CITY, OCTOBER 29, 2020 innovation to improve the human condition MISSION PRE-EVENT & ON-SITE RESOURCES FOR JOURNALISTS The Prix Galien Award recognizes outstanding achievements Galien Foundation events are conducted fully on the record, and in improving the global human condition through the development of innovative drugs and other treatments. we welcome and invite members of the media to participate as Sue Desmond-Hellmann, engaged stakeholders via on-site discussion, as well as via social The Prix Galien was created in 1970 in honor of Galien, Ethiopia Clinic site visit media, and to report on proceedings and outcomes. the father of medical science and modern pharmacology. th Worldwide the Prix Galien is regarded as the equivalent of 2020 : Prix Galien’s 50 Anniversary We certainly appreciate coverage of our events, but our priority Our diverse geographic reach is evident with the International the Nobel Prize in biopharmaceutical research. Prix Galien Awards, which launched in 1990, and is conducted is to help journalists explore and examine today’s key issues Africa Now! Senegal, Africa Selected As Permanent Host every two years to highlight the "best of the best" in research that and connect with the people and diverse organizations we bring for The International Prix Galien Awards Ceremony and brings dividends to patients across geographies with differing together that make the world a healthier place. The Prix Galien is more than an award: it is a movement with a Launch of the Prix Galien Africa. mandate to foster, recognize and reward excellence in scientific health needs. This desire to make biopharmaceutical and med To help facilitate your engagement with our speakers and innovation to improve the state of human health. Building on an The Prix Galien Golden Jubilee : 2020 is a landmark year tech innovation a global endeavor, bringing progress to patients in all corners of the world, will now be a key priority for the Prix stakeholders, we are delighted to work with you in the lead-up unrivaled network of top biomedical scientists including Nobel celebrating 50 years of progress in recognizing excellence in Galien community going forward. to our 2020 Forum and Ceremony on: Laureates in medicine, the Prix Galien manages an independent, biopharmaceutical and med tech innovations to improve the cross-functional and geographically diverse program of human condition. Under the sponsorship of the government of Senegal and the • Arranging interviews with key speakers and stakeholders events and sponsorships to brand “the best of the best” in new As a special feature our 50th Golden Jubilee year will honor WHO Regional Office for Africa, the Prix Galien Africa is our medicines and diagnostics. first truly region-wide initiative. It stands as a living tribute to • Reserving private spaces for on-site interviews the “global best of the very best” in: A- Pharmaceutical; Our scope is global, and our commitment to progress in medicine B- Biotechnology; C- Orphan and Rare diseases; D- Vaccines; the vision of Foundation co-founder, 1986 Nobel peace laureate • Sharing our latest programs and speaker lists is both measurable and concrete. Our members express this and E- Medical technology products. Eligibility will be drawn Elie Wiesel, who believed in medical innovation not only as an through the establishment of productive relationships to build from the 250 products awarded the Prix Galien by our 14 industrial policy asset but as a source of social progress, where • Providing hi-resolutions imagery (including photos lasting bridges between the commercial research enterprise member-country chapters since 1970, developed by more than private enterprise and public engagement combine to deliver a of people, spaces, logos, etc.) and local communities engaged in public policy, science, finance, 80 innovative companies, most of whom continue to bring new greater public good – health equity and access for all. academic research and the media. therapies for today’s patients with unmet medical needs. We invite all communities with a commitment In addition to recognizing advances in promising therapies, the The Galien Forum and Prix Galien USA Ceremony will take place to the conduct and promotion of life sciences FOR MORE INFORMATION AND REGISTER Prix Galien’s annual Roy Vagelos Pro Bono Humanum Award on October 29 in New York City at the Alexandria Center for Life innovation to contribute to this important work. FOR A PRESS PASS PLEASE CONTACT: for humanitarian achievements (www.galienfoundation.org/ Science and Museum of Natural History, respectively. During the index.php/2017/01/31/probono) brings a unique focus to the Ceremony, we will also announce the short list for the “Awards intersection between science, business and politics. The outcome of the Jubilee” – which will be selected by all past and present FINN PARTNERS we seek is guided by the synthesis principle that underpins the Committee members across the globe. Holmes Report & PR News / Midsize Agency of the Year CONTENT conduct of science itself: successful innovation where financing, The Golden Jubilee awards will be announced on December 11, CONTACT: physical assets, knowledge and skills are combined from many 2020 in Dakar in the presence of the President of the Senegalese • Kara Bradley, Account Supervisor sources to move new ideas quickly “from the bench to the Republic, H.E. Macky Sall, alongside many African heads of state PRIx GALIEN USA FOUNDING COMMITTEE ..........................4 bedside,” on behalf of patients everywhere. T: +1 646 213 7243 - [email protected] and ministers of health and/or environment, the WHO Director- 2020 AWARDS COMMITTEE .....................................................5 General as wel,l as hundreds of scientists and industry and innovation • Merissa Muller, Account Supervisor A truly global program present leaders. GALIEN FORUM .........................................................................6 T: +1 617 778 6633 - [email protected] Overview & Background in 15 countries* The best locale to pursue our mission is the African continent, “They participated in the Forum” whose young population is destined to double to 2.5 billion people Our program includes a review of contributions from a new HELPFUL LINKS : www.galienfoundation.org by 2050. According to the World Economic Forum, early-stage TESTIMONIALS FROM AROUND THE GLOBE ........................8 generation of innovators representing diverse sectors in health. entrepreneurial activity is nearly 15% higher in Africa than the • Prix Galien USA Our mission is to advance cross-cultural contacts and harmonize HALL OF FAME global average – yet while the continent is today home to 11% regulation, internal business processes, new information HISTORY OF THE PRIZE AND MEDAL...................................10 • Forum (latest programs, participants, registration of the world’s population, it accounts for a mere 1% of total technologies and public-private partnerships to remove barriers and reports) health spending and carries a crippling 25% of the global disease PRIx GALIEN USA ....................................................................11 to the commercialization of good medicines and expand across to burden. Taken together, these statistics reveal the progress • Pro Bono Humanum Award these benefits to all who need them. THE ROY VAGELOS PRO BONO HUMANUM AWARD..........12 inherent in what in a few years will be the world’s youngest and • Med StartUp Award potentially most productive population, but whose prospects WHO WAS GALEN ....................................................................13 • Prix Galien Around the Globe depend on more investment in health care as the key driver of PRIx GALIEN MEDSTART UP .................................................14 • Prix Galien Hall of Fame development. PRIx GALIEN USA WINNERS .................................................15 Summary of past 50 years of Prix Galien awards * Africa, Belgium, Canada, China, France, Germany, Greece, Italy, Netherlands, Poland, Russia, Spain, Switzerland, United Kingdom and the United States. “ Thanks to their gifts to society and their determination to alleviate and cure its woes, the scientists deserve to be ranked among prix galien usa the true friends of the human race.” prix galien usa Susan DESMOND-HELLMANN, MD, MPh Elie WiESEL in Memoriam Committee Chair COMMITTEE Honorary Founding President COMMITTEE Former Chief Executive Officer The Galien Foundation Bill & Melinda Gates Foundation 2OO7-2O1 1 Peace Nobel Laureate 2O2O Boston University Michael S. BROWN, MD Barry S. COLLER, MD Walter GiLBERT, PhD Joseph GOLDSTEiN, MD Richard AXEL, MD Linda B. BUCK, PhD Susannah FOX Laurie GLiMCHER, MD Joseph GOLDSTEiN, MD Nobel Laureate Vice President for Nobel Laureate Nobel Laureate Nobel Laureate Nobel Laureate Former Chief President and CEO Nobel Laureate Professor of Molecular Medical Affairs Professor Emeritus Professor of Molecular Co-director Fred Hutchinson Cancer Technology Officer Dana Farber Cancer Professor of Molecular Genetics and Internal and Physician-in-Chief, Harvard University Genetics and Internal The Kavli Institute for Research Center member, U.S. Department of Health Institute; Genetics and Internal Medicine Rockefeller University Medicine Brain Science. Columbia and Professor of Physiology and Human Services Professor of Medicine Medicine UT Southwestern UT, Southwestern University Medical Center and Biophysics
Load more

Recommended publications
  • Harvard Public Health Review Fall 2008
    Harvard Public Health Review Fall 2008 WILL DIGITAL HEALTH RECORDS FIX U.S. HEALTH CARE? INSIDE New HSPH Dean Julio Frenk XDR-TB marches on Health and taxes Surgical checklist Genes and environment Disasters in China and Myanmar Amazing alumni HARVA RD School of Pu blic Health DEAN OF THE FACULTY VISITING COMMITTEE DEAN’S COUNCIL Barry R. Bloom Steven A. Schroeder Gilbert Butler Chair Walter Channing, Jr. Harvard ALUMNI COUNCIL Barrie M. Damson Ruth L. Berkelman Mitchell L. Dong Jo Ivey Boufford The Harvard Public Health Review Officers John H. Foster Louis W. Cabot is published three times a year for Mark S. Clanton, mph ’90 A. Alan Friedberg Nils Daulaire supporters and alumni of the Harvard President C. Boyden Gray Nicholas N. Eberstadt School of Public Health. Its readers share Rajat Gupta Royce Moser, Jr., mph ’65 Cuthberto Garza a commitment to the School’s mission: Julie E. Henry, mph ’91 President-Elect Jo Handelsman advancing the public’s health through Stephen B. Kay Elsbeth Kalenderian, mph ’89 Gary King learning, discovery, and communication. Rachel King Secretary Jeffrey P. Koplan Nancy T. Lukitsh Risa Lavizzo-Mourey Harvard Public Health Review J. Jacques Carter, mph ’83* Beth V. Martignetti Bancroft Littlefield Harvard School of Public Health Immediate Past President David H. M. Matheson Nancy L. Lukitsh Office for Resource Development Richard L. Menschel Vickie M. Mays Third Floor, East Atrium Councilors Ahmed Mohiuddin Michael H. Merson 401 Park Drive 2005-2008 Adeoye Y. Olukotun, Anne Mills Boston, Massachusetts 02215 Bethania Blanco, SM ’73 mph ’83 Kenneth Olden (617) 384-8988 Marise S.
    [Show full text]
  • Vaccine Visions and Their Global Impact
    © 1998 Nature Publishing Group http://www.nature.com/naturemedicine COMMENTAR' Barry Bloom (a Howard Hughes Investigator at the Albert Einstein College of Medicine) and Roy Widdus (Coordinator of the Children's Vaccine Initiative) describe their vision of global implementation of vaccines, highlighting what has already been achieved and, perhaps more importantly, what remains to be done. They also call for further efforts to develop the broad collaborations required to achieve a new vision for global vaccine use. Vaccine visions and their global impact Shortly after the assassination of Prime tain because, as Lewis Thomas noted, we Minister Indira Gandhi in 1984, Jim BARRY R. BLOOM1 tend to take for granted the technologies 2 Grant, Administrator of UNICEF and & ROY WIDDUS that work best2• Hafdan Mahler, Director-General of The third great vision-the eradication World Health Organization (WHO), flew to New Delhi on an of paralytic poliomyelitis-is on the way to being achieved. extraordinary mission. They proposed to her surviving son, Although the scientific problems of creating safe and effective Rajiv, that instead of building a shrine or temple, he honor his polio vaccines were largely overcome by the 1960s, to have mother by making a commitment to immunize all the children global impact, political problems must also be overcome. Few of India against poliomyelitis by the end of the century. On countries want their infectious diseases to be publicly reported, December 6 and 7, 1996, in two National Vaccine Days, 121 and Ciro de Quadros of the Pan American Health Organization million Indian children were vaccinated against polio at came up with a brilliantly imaginative solution to a delicate 650,000 immunization posts by 2.6 million volunteers.
    [Show full text]
  • Investing in Our Common Future
    Investing in Our Common Future 2 Page 2 Global Strategy for Women’s and Children’s Health Background Paper for the Global Strategy for Women’s and Children’s Health: Investing in Our Common Future Working Papers of the Innovation Working Group - Version 2 Contents Page Introduction ……………………………………………………………………………………………………………..…… 5 Tore Godal, Special Adviser to the Prime Minister of Norway on Global Health - Co-Chair, Innovation Working Group, Global Strategy for Women’s and Children’s Health Scott C Ratzan, Vice-President, Global Health, Government Affairs & Policy, Johnson & Johnson - Co-Chair, Innovation Working Group, Global Strategy for Women’s and Children’s Health Executive Summary ………………………………………………………………………………………………………... 7 1. Results-Based Financing (RBF) In Service Demand and Delivery ……………………………...……… 11 Health Results Innovation Program Team: Darren Dorkin, Petra Vergeer, Rachel Skolnik and Jen Sturdy of the World Bank 2. The Health Systems Funding Platform ………………………………………………………………….…..…. 15 GAVI Alliance, The Global Fund to Fight AIDS, Tuberculosis and Malaria, World Bank and World Health Organization 3. Public-Private Partnership Models …………………………………………………………………….……..... 19 Barry Bloom, Professor of Public Health, Harvard School of Public Health Wendy Woods, Partner and Managing Director, Boston Consulting Group 4. Innovative Use of Mobile Phones and Related Information and Communication Technologies ….... 28 Scott C Ratzan, MD, Vice-President, Global Health, Government Affairs & Policy, Johnson & Johnson Denis Gilhooly, Executive Director, Digital He@lth Initiative, United Nations 5. New and Emerging Medical Technologies ……………………………………………………………..………. 36 Bill & Melinda Gates Foundation: Program Officers Andrew Serazin and Margaret Cornelius 6. Innovative Technologies for Women’s and Children’s Health ………………………………..………….. 39 Christopher J Elias, MD, MPH, President and CEO, PATH 7. Innovations on The Indian Scene that Relate to Improved Maternal and Newborn Health …..….
    [Show full text]
  • Curriculum Vitae David E
    CURRICULUM VITAE DAVID E. BLOOM April 2018 PRESENT POSITION Harvard T.H. Chan School of Public Health Clarence James Gamble Professor of Economics and Demography (since July 2001) Professor of Economics and Demography, July 1999–June 2001 Professor of Population and Health Economics, July 1996–June 1999 Contact information: Department of Global Health and Population Harvard T.H. Chan School of Public Health 665 Huntington Avenue Boston, Massachusetts 02115 Phone: (+1) 617-432-0866; (+1) 617-432-1168 Email: [email protected] (work) Email: [email protected] (personal) PREVIOUS POSITIONS Harvard Business School Visiting Professor (August 2011–June 2012) Harvard University, School of Public Health Chair, Department of Global Health and Population (September 2001–August 2011) Harvard University, Harvard Institute for International Development Deputy Director, July 1996–June 1999 Acting Executive Director, July 1995–June 1996 Columbia University, Department of Economics Chairman, July 1990–December 1993 Professor of Economics, July 1987–June 1996 Russell Sage Foundation Scholar-in-Residence, 1989–1990 academic year Harvard University, Department of Economics Visiting Professor of Economics, July 1987–March 1988 Paul Sack Associate Professor of Political Economy, July 1985–June 1987 Assistant Professor of Economics, July 1982–June 1985 Carnegie-Mellon University, School of Urban and Public Affairs Assistant Professor of Economics, September 1980–June 1982 PROFESSIONAL EXPERIENCE • Member, Lahore University of Management Sciences (LUMS) International Advisory Board (January 2018–present) • Founding Co-Editor, Journal of the Economics of Ageing (June 2012–present) • Member, Editorial Board, Demography India (2012–present) • Research Fellow, Institute of Labor Economics (IZA), Bonn, Germany (February 2012– present) • Member, Population Services International (PSI) Board of Trustees (February 2010– January 2016) • Member, John Snow Inc.
    [Show full text]
  • The United States' War on Aids Hearing Committee On
    THE UNITED STATES’ WAR ON AIDS HEARING BEFORE THE COMMITTEE ON INTERNATIONAL RELATIONS HOUSE OF REPRESENTATIVES ONE HUNDRED SEVENTH CONGRESS FIRST SESSION JUNE 7, 2001 Serial No. 107–17 Printed for the use of the Committee on International Relations ( Available via the World Wide Web: http://www.house.gov/international—relations U.S. GOVERNMENT PRINTING OFFICE 72–978PS WASHINGTON : 2001 For sale by the Superintendent of Documents, U.S. Government Printing Office Internet: bookstore.gpo.gov Phone: (202) 512–1800 Fax: (202) 512–2250 Mail: Stop SSOP, Washington, DC 20402–0001 VerDate 11-MAY-2000 13:00 Aug 07, 2001 Jkt 072978 PO 00000 Frm 00001 Fmt 5011 Sfmt 5011 F:\WORK\FULL\060701\72978 HINTREL1 PsN: HINTREL1 COMMITTEE ON INTERNATIONAL RELATIONS HENRY J. HYDE, Illinois, Chairman BENJAMIN A. GILMAN, New York TOM LANTOS, California JAMES A. LEACH, Iowa HOWARD L. BERMAN, California DOUG BEREUTER, Nebraska GARY L. ACKERMAN, New York CHRISTOPHER H. SMITH, New Jersey ENI F.H. FALEOMAVAEGA, American DAN BURTON, Indiana Samoa ELTON GALLEGLY, California DONALD M. PAYNE, New Jersey ILEANA ROS-LEHTINEN, Florida ROBERT MENENDEZ, New Jersey CASS BALLENGER, North Carolina SHERROD BROWN, Ohio DANA ROHRABACHER, California CYNTHIA A. MCKINNEY, Georgia EDWARD R. ROYCE, California ALCEE L. HASTINGS, Florida PETER T. KING, New York EARL F. HILLIARD, Alabama STEVE CHABOT, Ohio BRAD SHERMAN, California AMO HOUGHTON, New York ROBERT WEXLER, Florida JOHN M. MCHUGH, New York JIM DAVIS, Florida RICHARD BURR, North Carolina ELIOT L. ENGEL, New York JOHN COOKSEY, Louisiana WILLIAM D. DELAHUNT, Massachusetts THOMAS G. TANCREDO, Colorado GREGORY W. MEEKS, New York RON PAUL, Texas BARBARA LEE, California NICK SMITH, Michigan JOSEPH CROWLEY, New York JOSEPH R.
    [Show full text]
  • Research and Capacity Building for Global Health
    GLOBVAC – Research and Capacity Building for Global Health Midterm External Review Programme Global Health and Vaccination Research – GLOBVAC GLOBVAC – Research and Capacity Building for Global Health Midterm External Review Programme Global Health and Vaccination Research - GLOBVAC © The Research Council of Norway 2009 The Research Council of Norway P.O.Box 2700 St. Hanshaugen N–0131 OSLO Telephone: +47 22 03 70 00 Telefax: +47 22 03 70 01 [email protected] www.rcn.no/english Programme for Global Health and Vaccination Research, GLOBVAC www.rcn.no/globvac The report can be ordered at: www.forskningsradet.no/publikasjoner or green number telefax: +47 800 83 001 Coverdesign: Design et cetera AS Photo: Swimmer: Ablestock.com, mother and child: Chris Thomas Printing: Allkopi Number of copies: 1000 Oslo, November 2009 ISBN 978-82-12-02716-9 (printed version) ISBN 978-82-12-02717-6 (pdf) ii This midterm evaluation of the Programme for Global Health and Vaccination Research (GLOBVAC) was organised by the Research Council of Norway at the request of the Norwegian Agency for Development Cooperation – Norad. The evaluation was conducted by a panel of international experts. The draft of the Terms of Reference and the profile of the evaluation panel were approved by the Research Board of the Division for Strategic Priorities at the Research Council of Norway (DSS39/09) on 11 June 2009. The members of the evaluation panel were appointed and the final version of the Terms of Reference was approved by the Executive Director of the Division for Strategic Priorities. The panel members were: - Paul-Henri Lambert (chair), Professor Emeritus, Department of Pathology, University of Geneva - Zulfiqar Bhutta, Professor and Chair, Department of Paediatrics and Child Health, Aga Khan University - Barry Bloom, Former Dean, Harvard School of Public Health - Margaret Ann Liu, ProTherImmune & Foreign Adjunct Professor, Karolinska Institute iii Table of Contents 1.
    [Show full text]
  • Curriculum Vitae David E
    CURRICULUM VITAE DAVID E. BLOOM April 2015 PRESENT POSITION Clarence James Gamble Professor of Economics and Demography Harvard School of Public Health 665 Huntington Avenue, Boston, Massachusetts 02115, USA telephone: (+1) 617-432-0866 fax: (+1) 781-899-4212 email: [email protected] (work) email: [email protected] (personal) PREVIOUS POSITIONS Visiting Professor (August 2011-June 2012) Harvard Business School Chair, Department of Global Health and Population (September 2001-August 2011) Harvard University, School of Public Health Harvard University, Harvard Institute for International Development Deputy Director, July 1996–June 1999 Acting Executive Director, July 1995–June 1996 Harvard University, School of Public Health Professor of Economics and Demography, July 1999–present Professor of Population and Health Economics, July 1996–June 1999 Columbia University, Department of Economics Chairman, July 1990–December 1993 Professor of Economics, July 1987–June 1996 Russell Sage Foundation Scholar-in-Residence, 1989–1990 academic year Harvard University, Department of Economics Visiting Professor of Economics, July 1987–March 1988 Paul Sack Associate Professor of Political Economy, July 1985–June 1987 Assistant Professor of Economics, July 1982–June 1985 Carnegie-Mellon University, School of Urban and Public Affairs Assistant Professor of Economics, September 1980–June 1982 PROFESSIONAL EXPERIENCE • Member, Merck Vaccines Strategic Advisory Board, 2014- • Member, Editorial Board, International Journal of African Higher Education, 2013-
    [Show full text]
  • Hey. . . Stella! New Professorship to Honor President Wiesel MICHAEL DAMES Orsten N
    news&notes NOVEMBER 20, 1998 VOLUME 9, NUMBER 9 THE ROCKEFELLER UNIVERSITY Hey. Stella! New professorship to honor President Wiesel MICHAEL DAMES orsten N. Wiesel’s presidency will be honored with the creation of Tthe Torsten N. Wiesel Professorship. The professorship, which recognizes Wiesel’s leadership through- out a period of growth and revitaliza- tion, was announced last night (Nov. 19) by Board Chairman Emeritus Richard Furlaud at a dinner held in Wiesel’s honor at the Rainbow Room in Rockefeller Center. Members of the Board of Trustees and other leading benefactors of the university con- tributed gifts totalling $5.4 million to endow the chair. Retiring President Torsten Weisel will have a new pro- “The usual grant required to endow fessorship named in his honor. The announcement a university professorship is $3 million, was made last night at a party at the Rainbow Room. but the Board wanted this to be a special chair,” said Furlaud. “We set our sights The Torsten N. Wiesel Professorship on $5 million and exceeded it.” Three will be reserved for an outstanding million dollars will be designated as senior scientist recruited from outside endowment, and $2.4 million will be the university. A search for a senior sci- used to construct and equip a modern entist to fill the chair will commence Passersby did a double-take when they saw Frank Stella posing with his sculpture The Tail laboratory facility. shortly. last week in the Weiss Building. “Who is that man touching our art?” people wondered before realizing that it was the artist himself.
    [Show full text]
  • Hiv Vaccine Initiative (Hvi) World Health Organization
    HIV VACCINE INITIATIVE (HVI) WORLD HEALTH ORGANIZATION Meeting of the Vaccine Advisory Committee (VAC) Geneva, 21-23 February 2000 Summary Report and Recommendations INTRODUCTION WHO activities in the area of HIV vaccines were initiated in 1989, under the guidance of a “Biomedical Research Steering Committee”, chaired by Dr. Geoffrey Schild. In 1990 the former WHO Global Programme on AIDS established a Vaccine Development Unit guided by a “Vaccine Development Steering Committee”, which was chaired by Dr Hans Wigzell. With the establishment of UNAIDS in 1996, HIV vaccine activities were continued by the UNAIDS Vaccine Team, guided by its “Vaccine Advisory Committee” (VAC), chaired by Dr. Barry Bloom. The WHO-UNAIDS HIV Vaccine Initiative was established from January 2000, to take advantage of the complementary expertise of WHO and UNAIDS in the area of HIV vaccines. This was the first meeting of the VAC to provide guidance to the new WHO-UNAIDS Initiative, and it was attended by all 15 members of the Committee (Annex I). OPENING REMARKS The meeting was opened by Dr. Peter Piot, Executive Director of UNAIDS. Dr. Jose Esparza, Coordinator of the WHO-UNAIDS HIV Initiative, informed that the new initiative is based at the Health Technology and Pharmaceuticals (HTP) Cluster in WHO, and presented the apologies of Dr. Michael Scholtz, Executive Director of HTP, who could not attend the meeting. Dr Bjorn Melgaard, Director of the WHO Department of Vaccines and Biologicals, briefed the group on the recently launched Global Alliance for Vaccines and Immunization, of which WHO is a partner. WHO-UNAIDS HIV Vaccine Initiative (HVI), Health Technology and Pharmaceuticals World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland, Tel: (+41) 22 791 4248, Fax: (+41) 22 791 48 65, email:[email protected] 2 SUMMARY OF THE MEETING The meeting, which was chaired by Dr.
    [Show full text]
  • GHM 2 2 07 Final.Pub
    February 2007 Volume 5, Issue 1 Global Health Matters Fogarty International Center (NIH/HHS) “Science for Glob al Health ” Fogarty Framework Programs in Global Health INSIDE THIS ISSUE: World-renowned research “Framework Programs for A repeated theme Letter from the Director 2 scientists and educators from Global Health.” throughout the meeting all corners of the globe—U.S., was the catalytic value of Latin America, Africa, China The programs link schools bringing all these strands Fogarty Ellison Fellows 3 and Russia—gathered on the from diverse disciplines on a together as a truly trans- Share NIH campus on November 30 single or on multiple campus program. The flip and December 1, 2006, to campuses—such as Schools of side, however, was the Foreign Tracking System 5 participate in the first Public Health and Medicine repeated theme of the international networking with Schools of Engineering, challenges—administrative meeting for the FIC Law, Business, International and cultural—of working Malaria Progress and 5 Relations, Communications across traditional Perspective and others—to create joint boundaries within the activities, curricula and institutions. FIC Strategic Plan 6 educational opportunities in global health. In a series of short presentations, panel Across the Center 7 In many cases, the process of discussions and break out preparing an application was working groups Bioethics Training Pro- 7 the first time some members of participants discussed the gram in Egypt the global health community various models they are at a university learned of each using to create global Dr. Flora Katz, Program Director, other’s work. health programs. Framework, FIC and Dr.
    [Show full text]
  • Global Health Governance, Volume IV Issue 2: Spring 2011
    Global Health Security: Closing the Gaps in Responding to Infectious Disease Emergencies Jennifer B. Nuzzo and Gigi Kwik Gronvall Rising concerns about the human, political, and economic costs of emerging infectious disease threats and deliberate epidemics have highlighted the important connection between global public health and security. This realization has led security communities, particularly in the U.S., to seek ways to bolster the international health response to public health emergencies as a means of protecting national security. While there have been important recent efforts to strengthen international response to infectious disease threats, there are areas that deserve more attention from both the health and security communities. In this article, we describe two important gaps in international frameworks that govern the response to global public health threats which can negatively affect the security of states: (1) despite attempts to strengthen international rules for responding to public health emergencies, there continues to be strong disincentives for states to report disease outbreaks; and (2) systems for detecting and responding to outbreaks of infectious diseases are hindered by a lack of standards of practice for sharing biological samples and specimens. To address these gaps in global governance of infectious disease threats, additional incentives are needed for states to report disease outbreaks to the international community; there should be greater enforcement of countries’ international health obligations; and both political and scientific communities should develop workable practice standards for sharing biological samples of all types. INTRODUCTION The anthrax attacks of 2001, the rapid global spread of severe acute respiratory syndrome (SARS) in 2003, the 2009 influenza A (H1N1) pandemic, and the recent E.
    [Show full text]
  • Be a Part of the Solution
    This document is updated as of June 24, 2021 1 COVID-19 Resources for India: Be a Part of the Solution A Communication Implementation Guide 2nd Edition Updated as of June 24, 2021 #COVIDFreeIndia This document is updated as of June 24, 2021 2 India’s COVID-19 Crisis in 2021 India is in the middle of its worst health crisis in recent history, with the unprecedented second wave of COVID-19 infecting and killing millions of people. A decrease in the number of daily cases earlier this year led to a sense of complacency and decreased compliance with healthy behaviors proven to prevent COVID-19 transmission, such as wearing masks, hand washing, and physical distancing. In addition, the increased usage of social media has also led to uncontrolled spreading of misinformation and disinformation on COVID-19 prevention, treatment, prognosis, management, and vaccines. This spread of misinformation and disinformation through social media and other channels is arguably one of the major contributors to the current crisis and is likely leading to panic, uncertainty, and mismanagement of COVID-19. Our overarching goal at the Harvard T.H. Chan School of Public Health - India Research Center and Project SANCHAR is to do our part in the mitigation of the crisis by providing reliable and accurate information on COVID-19 prevention and promote prosocial behaviors drawing on the latest possible evidence. To this end, we are sharing this COVID-19 Communication Implementation Guide with partners and affiliates with easy-to-understand facts, myth-busters, and guidelines on COVID-19 prevention, and maintaining physical, social and emotional wellbeing.
    [Show full text]